A Phase I, Multiple-Dose Study of the Safety and Tolerability of Single Agent REGN421 Administered Every 3 Weeks in Patients with Advanced Solid Malignancies

Objective

Clinical trial of investigational drug REGN421 given through an intravenous (IV) infusion.

IRB Protocol Number

09-0065

Principal Investigator(s)

ANTONIO JIMENO

Cancer Trials

• All Cancers

Sponsor(s)

Regeneron Pharmaceuticals, Inc.

Contact

SHARON HECKER at 720-848-0667
or SHARON.HECKER@ucdenver.edu

Eligibility and Other Participant Information

What To Expect : A screening period to determine eligibility. A treatment period that can last as long as you are responding well to the study drug. A follow up period will consist of a clinic visit at 15, 30 and 60 days after you stop taking the study drug. // Eligibility criteria include but are not limited to 18 years or older with advanced solid tumor(s).